COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
COVID-19 Wastewater Activity in U.S.
- More than half of U.S. states are seeing significant Covid-19 activity in wastewater, with 26 states reporting high or very high virus levels at different sites.
President Biden's COVID-19 Isolation and Vaccine Development
- President Biden is isolating after testing positive for Covid-19 for the third time, while the administration now treats Covid-19 as a routine respiratory virus. Vaccine companies like Novovax, Moderna, and Pfizer are developing new vaccines targeting different variants.
Trade with 70% Backtested Accuracy
Analyst Views on MEDI
No data
About the author
Eight Stock Selections to Capitalize on a Robust Sector of the Market
Healthcare Sector Valuation: The U.S. healthcare sector is currently attractively priced, with a forward price/earnings (P/E) ratio of 18.2, appealing to investors wary of the overall market's high valuations.
Comparison with S&P 500: The healthcare sector's forward P/E is a 12% premium over its 10-year average, while the broader S&P 500 has a forward P/E of 22.4, which is a 19% premium to its historical average.
Eli Lilly Dominance: The Impact of a Single Stock on Pharma ETF Performance
Eli Lilly's Influence on Healthcare ETFs: Eli Lilly has become a significant driver in the pharmaceutical ETF market, with around 15 ETFs allocating double-digit weights to the company, making it a key player in healthcare fund performance.
Strong Q3 Performance: In Q3, Eli Lilly reported a 54% year-over-year revenue increase, surpassing Wall Street expectations, and raised its full-year sales and EPS guidance, solidifying its status as a growth engine in the sector.
Major ETF Allocations: Leading ETFs like iShares US Pharmaceuticals ETF and VanEck Pharmaceutical ETF have substantial allocations to Lilly, with weights of 26.9% and 24.1% respectively, indicating a strong reliance on the stock for performance.
Concerns Over Concentration: While Eli Lilly's growth is beneficial for investors, there are concerns about the potential over-dependence of ETFs on a single stock, as Lilly's performance continues to significantly impact the broader pharmaceutical ETF market.
Biotech Makes a Comeback: Reasons to Add These Rising Stocks to Your Portfolio Today.
Biotech Sector Recovery: Biotech stocks are rebounding after a four-year downturn, with the SPDR S&P Biotech ETF (XBI) rising 25% year-to-date as of October 31.
Performance Comparison: The biotech sector's performance has outpaced the S&P 500 by 9 percentage points during the same period.
Future Outlook: Analysts believe that the strength of the biotech sector is likely to persist, indicating potential opportunities for investors.
Investment Timing: Experts suggest that it is not too late for investors to enter the biotech market.
Is It the Right Moment to Invest in UnitedHealth-Focused ETFs?
Berkshire Hathaway Investment: Berkshire Hathaway acquired over 5 million shares of UnitedHealth (UNH) worth $1.57 billion, boosting UNH's stock price by 12% on August 15, 2025, amidst other investments from notable hedge funds.
Earnings and Projections: UnitedHealth's second-quarter earnings fell short of estimates due to high operating costs, with projected revenues for 2025 now between $445.5 billion and $448 billion, while adjusted net EPS is expected to be at least $16, down from previous guidance.
Stock Performance: UNH shares have significantly underperformed, falling 47.5% over the past year, with a current valuation of 10.83X forward P/E, leading to concerns among investors despite recent acquisitions strengthening its market presence.
Investment Recommendations: Analysts suggest investing in UNH-heavy ETFs to mitigate company-specific risks, with various price targets set for UNH shares ranging from $198 to $440, reflecting mixed sentiments about the stock's future performance.
"Invest in ETFs the Warren Buffett Way"
Warren Buffett's Investment Moves: Berkshire Hathaway disclosed new investments, including over 5 million shares in UnitedHealth Group valued at $1.6 billion, which led to an 11% stock increase.
Focus on Homebuilders: Buffett has increased stakes in homebuilding companies like Lennar and D.R. Horton, indicating confidence in the housing market amid easing mortgage rates.
Consumer Staples Investments: Buffett expanded his positions in food and beverage companies such as Constellation Brands and Domino’s Pizza, reflecting a strategy focused on non-cyclical sectors that perform well during economic slowdowns.
Reduction in Apple and Bank of America Stakes: Berkshire Hathaway has significantly reduced its holdings in Apple by 69% and Bank of America by selling 26 million shares, continuing a trend of trimming large positions amidst changing market dynamics.
UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk
UnitedHealth Group Stock Performance: UnitedHealth Group's stock has plummeted over 50% year-to-date due to weak Q1 earnings and a lowered full-year outlook, prompting investors to consider ETFs like Harbor Health Care ETF (MEDI) and T. Rowe Price Health Care ETF (TMED) for diversified exposure.
ETF Details and Ratings: The MEDI ETF has a Strong Buy consensus with a 42.79% upside potential, while the TMED ETF holds a Moderate Buy rating with a 41.31% upside potential; both provide indirect exposure to UNH stock, reducing investment risk.
Eight Stock Selections to Capitalize on a Robust Sector of the Market
Healthcare Sector Valuation: The U.S. healthcare sector is currently attractively priced, with a forward price/earnings (P/E) ratio of 18.2, appealing to investors wary of the overall market's high valuations.
Comparison with S&P 500: The healthcare sector's forward P/E is a 12% premium over its 10-year average, while the broader S&P 500 has a forward P/E of 22.4, which is a 19% premium to its historical average.
Eli Lilly Dominance: The Impact of a Single Stock on Pharma ETF Performance
Eli Lilly's Influence on Healthcare ETFs: Eli Lilly has become a significant driver in the pharmaceutical ETF market, with around 15 ETFs allocating double-digit weights to the company, making it a key player in healthcare fund performance.
Strong Q3 Performance: In Q3, Eli Lilly reported a 54% year-over-year revenue increase, surpassing Wall Street expectations, and raised its full-year sales and EPS guidance, solidifying its status as a growth engine in the sector.
Major ETF Allocations: Leading ETFs like iShares US Pharmaceuticals ETF and VanEck Pharmaceutical ETF have substantial allocations to Lilly, with weights of 26.9% and 24.1% respectively, indicating a strong reliance on the stock for performance.
Concerns Over Concentration: While Eli Lilly's growth is beneficial for investors, there are concerns about the potential over-dependence of ETFs on a single stock, as Lilly's performance continues to significantly impact the broader pharmaceutical ETF market.
Biotech Makes a Comeback: Reasons to Add These Rising Stocks to Your Portfolio Today.
Biotech Sector Recovery: Biotech stocks are rebounding after a four-year downturn, with the SPDR S&P Biotech ETF (XBI) rising 25% year-to-date as of October 31.
Performance Comparison: The biotech sector's performance has outpaced the S&P 500 by 9 percentage points during the same period.
Future Outlook: Analysts believe that the strength of the biotech sector is likely to persist, indicating potential opportunities for investors.
Investment Timing: Experts suggest that it is not too late for investors to enter the biotech market.
Is It the Right Moment to Invest in UnitedHealth-Focused ETFs?
Berkshire Hathaway Investment: Berkshire Hathaway acquired over 5 million shares of UnitedHealth (UNH) worth $1.57 billion, boosting UNH's stock price by 12% on August 15, 2025, amidst other investments from notable hedge funds.
Earnings and Projections: UnitedHealth's second-quarter earnings fell short of estimates due to high operating costs, with projected revenues for 2025 now between $445.5 billion and $448 billion, while adjusted net EPS is expected to be at least $16, down from previous guidance.
Stock Performance: UNH shares have significantly underperformed, falling 47.5% over the past year, with a current valuation of 10.83X forward P/E, leading to concerns among investors despite recent acquisitions strengthening its market presence.
Investment Recommendations: Analysts suggest investing in UNH-heavy ETFs to mitigate company-specific risks, with various price targets set for UNH shares ranging from $198 to $440, reflecting mixed sentiments about the stock's future performance.
"Invest in ETFs the Warren Buffett Way"
Warren Buffett's Investment Moves: Berkshire Hathaway disclosed new investments, including over 5 million shares in UnitedHealth Group valued at $1.6 billion, which led to an 11% stock increase.
Focus on Homebuilders: Buffett has increased stakes in homebuilding companies like Lennar and D.R. Horton, indicating confidence in the housing market amid easing mortgage rates.
Consumer Staples Investments: Buffett expanded his positions in food and beverage companies such as Constellation Brands and Domino’s Pizza, reflecting a strategy focused on non-cyclical sectors that perform well during economic slowdowns.
Reduction in Apple and Bank of America Stakes: Berkshire Hathaway has significantly reduced its holdings in Apple by 69% and Bank of America by selling 26 million shares, continuing a trend of trimming large positions amidst changing market dynamics.
UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk
UnitedHealth Group Stock Performance: UnitedHealth Group's stock has plummeted over 50% year-to-date due to weak Q1 earnings and a lowered full-year outlook, prompting investors to consider ETFs like Harbor Health Care ETF (MEDI) and T. Rowe Price Health Care ETF (TMED) for diversified exposure.
ETF Details and Ratings: The MEDI ETF has a Strong Buy consensus with a 42.79% upside potential, while the TMED ETF holds a Moderate Buy rating with a 41.31% upside potential; both provide indirect exposure to UNH stock, reducing investment risk.
